Related references
Note: Only part of the references are listed.Annual banned-substance review: analytical approaches in human sports drug testing
Mario Thevis et al.
DRUG TESTING AND ANALYSIS (2013)
Plasma Stability-Dependent Circulation of Acyl Glucuronide Metabolites in Humans: How Circulating Metabolite Profiles of Muraglitazar and Peliglitazar Can Lead to Misleading Risk Assessment
Donglu Zhang et al.
DRUG METABOLISM AND DISPOSITION (2011)
The List of Prohibited Substances and Methods in Sport: Structure and Review Process by the World Anti-Doping Agency
Irene Mazzoni et al.
JOURNAL OF ANALYTICAL TOXICOLOGY (2011)
Acyl Glucuronides: The Good, The Bad and The Ugly
Sophie L. Regan et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2010)
Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (efaproxyn) plus whole-brain radiation therapy for brain Metastases
Charles Scott et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2007)
Detection of manipulation in doping control urine sample collection:: a multidisciplinary approach to determine identical urine samples
Mario Thevis et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2007)
Validation of new methods
Frank T. Peters et al.
FORENSIC SCIENCE INTERNATIONAL (2007)
Mass spectrometric characterization of efaproxiral (RSR13) and its implementation into doping controls using liquid chromatography atmospheric pressure ionization-tandem mass spectrometry
M Thevis et al.
JOURNAL OF MASS SPECTROMETRY (2006)
Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases
JH Suh et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Detection in urine of efaproxiral (RSR13), a potential doping agent, by a routine screening procedure based on methylation followed by gas chromatography/mass spectrometry
C Jiménez et al.
ANALYTICA CHIMICA ACTA (2004)
Acyl glucuronide drug metabolites: Toxicological and analytical implications
M Shipkova et al.
THERAPEUTIC DRUG MONITORING (2003)
A Phase I study of RSR13, a radiation-enhancing hemoglobin modifier: Tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics
BD Kavanagh et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2001)
Allosteric modification of oxygen delivery by hemoglobin
JA Wahr et al.
ANESTHESIA AND ANALGESIA (2001)
RSR13, a potential athletic performance enhancement agent: detection in urine by gas chromatography/mass spectrometry
A Breidbach et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2001)
Share Paper
